Vera Therapeutics announced a major milestone in drug development on January 7, 2026, when the U.S. Food and Drug Administration granted Priority Review to the Biologics License Application (BLA) for atacicept, a novel treatment for immunoglobulin A nephropathy (IgAN) in adults. This regulatory advancement reported by GlobalNewswire.com, positions atacicept as a potential breakthrough therapy for patients with one of the most serious autoimmune kidney diseases, with an FDA decision expected by July 7, 2026.
The Priority Review designation underscores the significant unmet medical need in the IgAN treatment landscape. IgAN is a progressive autoimmune disease affecting the kidneys, and at least 50% of patients develop end-stage kidney disease or kidney failure, resulting in considerable physical and lifestyle impacts. The lack of disease-modifying treatments that address the root cause of the condition has left physicians and patients with limited therapeutic options.
Atacicept represents a distinct therapeutic approach through its dual targeting of BAFF and APRIL, two cytokines crucial to B-cell autoantibody production. If approved, it would be the first B-cell modulator specifically designed to target both of these factors for IgAN treatment. The drug’s novel mechanism addresses the upstream source of the disease, offering a fundamentally different strategy compared to existing therapies.
The BLA submission is supported by compelling clinical evidence from the ORIGIN 3 Phase 3 trial, a global, multicenter trial involving 431 adults with IgAN. In a prespecified interim analysis at 36 weeks, atacicept demonstrated statistically significant and clinically meaningful proteinuria reduction, with participants achieving a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR). When compared to placebo, atacicept showed a 42% reduction in UPCR, a clinically important advantage that met the trial’s primary endpoint with p<0.0001. Importantly, the safety profile of atacicept was favorable and comparable to placebo throughout the trial.
Beyond the 36-week interim analysis, extended follow-up through 96 weeks showed continued improvements in biomarkers and disease indicators, with atacicept demonstrating further enhancements in Gd-IgA1 levels, hematuria, and proteinuria, while stabilizing kidney function as measured by estimated glomerular filtration rate (eGFR). These results were presented at the American Society of Nephrology Kidney Week and published in the New England Journal of Medicine.
Another significant achievement for atacicept is its FDA Breakthrough Therapy Designation for IgAN treatment, which recognizes the potential for substantial improvement over available therapies on clinically significant endpoints. The designation reflects the agency’s assessment that atacicept may represent a meaningful advance in treatment options for this serious condition.
From a patient convenience perspective, atacicept offers a considerable advantage: it will be self-administered at home as a once-weekly subcutaneous injection via autoinjector. This approach enhances accessibility and quality of life by eliminating the need for frequent clinical visits.
Vera Therapeutics’ atacicept has been administered to more than 1,500 patients across various clinical trials and disease areas, providing an extensive safety database. The company is exploring atacicept’s potential in additional autoimmune kidney diseases and is conducting the PIONEER trial to evaluate its effectiveness in other B-cell-driven conditions, including membranous nephropathy and focal segmental glomerulosclerosis.
The July 2026 decision date represents a pivotal moment for patients with IgAN, potentially bringing a transformative treatment option to a disease with significant unmet medical needs.
